Monalizumab is a first-in-class immune checkpoint inhibitor that targets Natural Killer Group 2A (NKG2A). Monalizumab increased degranulation and IFN-_ production by NKG2A+ NK cell against HLA-E+ target cells, thereby promoting NK cell effector functions.